Abstract: The present invention concerns ternary co-amorphous forms including a drug compound, a nutraceutical, or a dietary supplement in combination with a protein and a water-soluble polymer. Co-amorphous forms are a combination of three or more components that form a homogeneous amorphous system where the components are intimately mixed on the molecular level. The ternary co-amorphous forms of the invention provide increased solubility and dissolution rate of drug compounds, nutraceuticals, and dietary supplements. This in turn increases the bioavailability of these compounds.

Abstract: The invention relates to a co-amorphous form of beta-lactoglobulin and a drug substance selected from olaparib and abiraterone acetate, wherein the concentration of the drug substance in the co-amorphous form is from 10% to 90% w/w based on the total weight of the co-amorphous form. I also related to compositions comprising a co-amorphous form, and a dosage regime for the treatment of cancer such as prostate cancer, notably castration-resistant prostate cancer.

Abstract: The present invention relates to co-amorphous forms of a drug substance and a protein, more particularly beta-lactoglobulin, wherein the purity of the beta-lactoglobulin is at least 92% (w/w) of the total amount of protein comprised in the co-amorphous form. The present invention also relates to compositions, such as pharmaceutical compositions, comprising the co-amorphous form.